Live in the Nasdaq Marketside in the heart of New York City's Times Square, this is Fast

Money. Here's what's on tap tonight. Deep impact, the growing power of obesity drugs

on full display today, Lily and Novo Nordic soaring while the dialysis, diabetes and

device makers, Paul Hart, a deep dive on how the street is now viewing these drugs as

game changers for the future of health care. Plus, unhappy feet, investors not sliding

on chairs of Birkensock and its first day of trading the stock closing nearly $6

below its offer price. We'll take a look at why so many of the recent IPOs have hit

the street like two left feet. And later, inside gold and silver's bright and shiny

week, breaking down the banks ahead of earning season, and is more turbulence in the forecast

for Delta, we've got the options action there. I'm Melissa Lee, coming to you live from

Studio B at the Nasdaq on the desk tonight, Tim Seymour, Karen Feinerman, Diodami and Julie

Beale. We start off with the monster implications of a potential do-it-all drug, chairs of Novo

Nordic soaring over 6% today, closing just shy of its all-time high. The move coming

after early tests suggest its diabetes and weight loss drug ozempic could be used to treat

kidney failure as well. The new sending shares of med tech companies like Davida, Fersenius

and Baxter International plunging, Baxter in fact hitting its lowest level in nearly

eight years. And this could be just the start ozempic and drugs like it could find uses

in treating alcohol and drug addiction, Alzheimer's, even a lowering blood pressure just to name

a few. So what could such a potentially far-reaching treatment mean for the health care space? We

always say the pendulum swings too far. So you wonder right now if we've swung too far in terms

of it being the miracle drug guy. In terms of names like you mentioned a few, I'll throw

another one, Medtronic, it swung way too far. I mean this is one of the great companies. I mean

...